| Alpha-emitters and targeted alpha therapy in oncology: from basic science to clinical investigations M Makvandi, E Dupis, JW Engle, FM Nortier, ME Fassbender, S Simon, ... Targeted oncology 13, 189-203, 2018 | 149 | 2018 |
| A PET imaging agent for evaluating PARP-1 expression in ovarian cancer M Makvandi, A Pantel, L Schwartz, E Schubert, K Xu, CJ Hsieh, C Hou, ... The Journal of clinical investigation 128 (5), 2116-2126, 2018 | 119 | 2018 |
| Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex A Riad, C Zeng, CC Weng, H Winters, K Xu, M Makvandi, T Metz, S Carlin, ... Scientific reports 8 (1), 16845, 2018 | 114 | 2018 |
| A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy M Makvandi, K Xu, BP Lieberman, RC Anderson, SS Effron, HD Winters, ... Cancer research 76 (15), 4516-4524, 2016 | 91 | 2016 |
| Rapid Cu-Catalyzed [211At]Astatination and [125I]Iodination of Boronic Esters at Room Temperature SW Reilly, M Makvandi, K Xu, RH Mach Organic letters 20 (7), 1752-1755, 2018 | 74 | 2018 |
| A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers E George, H Kim, C Krepler, B Wenz, M Makvandi, JL Tanyi, E Brown, ... JCI insight 2 (1), 2017 | 70 | 2017 |
| Photochemical intermolecular [3σ+ 2σ]-cycloaddition for the construction of aminobicyclo [3.1. 1] heptanes Y Zheng, W Huang, RK Dhungana, A Granados, S Keess, M Makvandi, ... Journal of the American Chemical Society 144 (51), 23685-23690, 2022 | 62 | 2022 |
| Improved safety and efficacy of 213 Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with L-lysine HS Chan, MW Konijnenberg, T Daniels, M Nysus, M Makvandi, E de Blois, ... EJNMMI research 6, 1-11, 2016 | 56 | 2016 |
| TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death C Zeng, CC Weng, ME Schneider Jr, L Puentes, A Riad, K Xu, ... Cell death discovery 5 (1), 58, 2019 | 54 | 2019 |
| Targeting PARP-1 with alpha-particles is potently cytotoxic to human neuroblastoma in preclinical models M Makvandi, H Lee, LN Puentes, SW Reilly, KS Rathi, CC Weng, ... Molecular cancer therapeutics 18 (7), 1195-1204, 2019 | 47 | 2019 |
| [18F] FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer CE Edmonds, M Makvandi, BP Lieberman, K Xu, C Zeng, S Li, C Hou, ... American journal of nuclear medicine and molecular imaging 6 (1), 94, 2016 | 47 | 2016 |
| Examination of diazaspiro cores as piperazine bioisosteres in the olaparib framework shows reduced DNA damage and cytotoxicity SW Reilly, LN Puentes, K Wilson, CJ Hsieh, CC Weng, M Makvandi, ... Journal of medicinal chemistry 61 (12), 5367-5379, 2018 | 41 | 2018 |
| Effects of nicotine on cardiovascular remodeling in a mouse model of systemic hypertension ES Colombo, J Davis, M Makvandi, M Aragon, SN Lucas, ML Paffett, ... Cardiovascular toxicology 13, 364-369, 2013 | 32 | 2013 |
| Cell-proliferation imaging for monitoring response to CDK4/6 inhibition combined with endocrine-therapy in breast cancer: comparison of [18F] FLT and [18F] ISO-1 PET/CT A Elmi, M Makvandi, CC Weng, C Hou, AS Clark, RH Mach, DA Mankoff Clinical Cancer Research 25 (10), 3063-3073, 2019 | 31 | 2019 |
| PARP-1–Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma H Lee, A Riad, P Martorano, A Mansfield, M Samanta, V Batra, RH Mach, ... Journal of Nuclear Medicine 61 (6), 850-856, 2020 | 30 | 2020 |
| Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo RC Anderson, M Makvandi, K Xu, BP Lieberman, C Zeng, DA Pryma, ... Nuclear medicine and biology 43 (12), 752-758, 2016 | 30 | 2016 |
| PARP-1 Expression Quantified by [18F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy S Sander Effron, M Makvandi, L Lin, K Xu, S Li, H Lee, C Hou, DA Pryma, ... Cancer Biotherapy and Radiopharmaceuticals 32 (1), 9-15, 2017 | 29 | 2017 |
| Abstract CT234: A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic … KAR Binder, R Mick, M O'Hara, U Teitelbaum, T Karasic, C Schneider, ... Cancer research 79 (13_Supplement), CT234-CT234, 2019 | 28 | 2019 |
| The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer M Makvandi, ED Tilahun, BP Lieberman, RC Anderson, C Zeng, K Xu, ... Biochemical and biophysical research communications 467 (4), 1070-1075, 2015 | 26 | 2015 |
| A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1 … KAR Binder, R Mick, M O'Hara, U Teitelbaum, T Karasic, C Schneider, ... Cancer Research 79 (13), 2019 | 25 | 2019 |
